Clinical Trial Update: Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating sitagliptin combined with gemcitabine and albumin-bound paclitaxel in pancreatic ductal adenocarcinoma patients; status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound) (paclitaxel albumin-bound)
• Gemcitabine (Gemcitabine)
• Sitagliptin (sitagliptin)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: PDAC - Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: UNKNOWN